Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
20 Fevereiro 2025 - 6:00PM
Business Wire
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it
will host its fourth quarter and full year 2024 investor update
conference call and webcast at 8:30 a.m. Eastern Time on Thursday,
February 27, 2025. Individuals interested in participating in the
call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525
(international) using conference ID number and event passcode
2530602. To access the webcast, please visit the Investors section
of Ironwood’s website at www.ironwoodpharma.com.
The call will be available for replay via telephone starting
Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern
Time, running through 11:59 p.m. Eastern Time on Thursday, March
13, 2025. To listen to the replay, dial (800) 770-2030 (U.S. and
Canada) or (609) 800-9909 (international) using conference ID
number 2530602. The archived webcast will be available on
Ironwood’s website for 1 year beginning approximately one hour
after the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology
company developing and commercializing life-changing therapies for
people living with gastrointestinal (GI) and rare diseases.
Ironwood is advancing apraglutide, a next-generation, long-acting
synthetic GLP-2 analog being developed for short bowel syndrome
patients who are dependent on parenteral support. In addition,
Ironwood has been a pioneer in the development of LINZESS®
(linaclotide), the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS-C) or
chronic idiopathic constipation (CIC). LINZESS is also approved for
the treatment of functional constipation in pediatric patients ages
6-17 years old. Building upon our history of innovation, we keep
patients at the heart of our R&D and commercialization efforts
to reduce the burden of diseases and address significant unmet
needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in
Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors
on our website at www.ironwoodpharma.com. In addition, follow us on
X and on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250213887685/en/
Company contact: Greg Martini
gmartini@ironwoodpharma.com
Investors: Precision AQ (formerly Stern Investor
Relations) Stephanie Ascher stephanie.ascher@precisionaq.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
